EMEIS SA (EMEIS) fair value: what the stock is really worth
We calculate from audited financials what EMEIS SA is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
- Compare price with fair valuebelow fair value = cheap, above = expensive
- Check the quality50 and up solid, 75 and up strong
- Watch it or check another stockalert when fair value or trend changes
At a glance
Below-average quality, trading 57% below our fair value of €29.37.
As of Sep 11, 2026, the fair value of EMEIS SA is €29.37 per share against a price of €12.62, so the fair value sits 133% above the price. A model estimate from reported figures, not an analyst target.
Fair value as of: Sep 11, 2026
From 9 valuation models · updated today
Share price −9.9% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The large discount to fair value meets weak quality (37/100). That raises the risk this is a value trap rather than a bargain.
- The model range is unusually wide (€9.22 to €29.37). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 11, 2026.
How to read this chart
60‑month range €4.79 – €7,041 · fair‑value band €9.22 – €29.37 · the €12.62 price screens below the €29.37 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 11, 2026.
Analysis
EMEIS SA (EMEIS) currently trades at €12.62, while our model-based Fair Value estimate is €29.37, implying the stock looks roughly 57.0% undervalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of €28.72 per share, and 5 of the 9 models we run sit above the €12.62 price. Bear case: the Growth DCF group reads lowest at €3.50, and 4 of the 9 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, EMEIS SA generated revenue of €5.9B at a net margin of −5.1%. Revenue grew 4.3% year over year. It earns a return on equity of −19.1%. Net debt stands at €8.3B. Fundamentals as of Sep 11, 2026
Scenario range: €9.22 (bear) to €29.37 (bull), the price of €12.62 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 22% below its 52-week high and 27% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 133%, EMEIS screens cheaper than that median.
Fair Value models
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
All 9 models by family
Widest divergence: DCF Models (€28.72) versus Growth DCF (€3.50). Highest evidence: FCF DCF (74).
Notify me when EMEIS reaches fair value
Put EMEIS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 11, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 38 · Market factors (momentum, volatility) 45
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
emeis Société anonyme operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals.
Full company description
emeis Société anonyme operates nursing homes, assisted-living facilities, post-acute and rehabilitation hospitals, and psychiatric hospitals. Its services include concierge, housekeeping, ironing, internet connection, TV, telephone, free shuttles, catering and event organization, access to common areas, logistics support, DIY and gardening assistance, IT support, beauty and relaxation treatments, furniture on rent, fitness and wellness areas, and medical visits. The company's post-acute and rehabilitation hospitals offer services for geriatrics, musculoskeletal, nervous system, cardiovascular, hematology, and oncology conditions, as well as patients in a persistent vegetative state or in a minimally conscious state. Its psychiatric hospitals provide services for the patients with mood disorders, anxiety disorders, obsessive-compulsive disorders, addictions, eating disorders, sleep disorders, personality disorders, schizophrenic disorders, autism spectrum disorders, psychotraumatic disorders, neurodegenerative diseases, Perinatal psychiatry, and burn-out. It operates in France, Belgium, Spain, Italy, Ireland, Switzerland, Austria, Germany, the United Kingdom, the Czech Republic, Poland, the Netherlands, Luxembourg, Portugal, Brazil, Russia, Slovenia, Uruguay, Colombia, Mexico, Chile, Latvia, Croatia, and China. The company was founded in 1989 and is headquartered in Puteaux, France.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
EMEIS SA reported revenue of €5.9B in FY2025 versus €4.3B in FY2021, a compound +8.2%/yr. Reported net income was −€298M in FY2025.
Watch EMEIS, get fair value alerts →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Emeis (WBO:ORP2) (H1 2026) Earnings Call Highlights: Strong Revenue Growth and Margin Expansion ...
- emeis: Availability of the 2026 Half-Year Financial Report
- emeis: 2026 Half-Year Results
- emeis: Half-Year Review (H1 2026) of the Liquidity Agreement Entered Into With Natixis Oddo BHF
Peer Group
Medical Care Facilities · 257 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
What the price implies (reverse DCF)
The inverse question: what free-cash-flow growth must EMEIS SA deliver for ten years so that today's price is fair in our DCF model? Same formula, same discount rate as the fair value.
The price demands less growth than the company recently delivered: even a weaker business would justify the price. Ranking of the largest stocks →
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: French Stocks
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Sep 11, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $405.00 | $547.67 | +35% |
| Fresenius SE FRE | €44.69 | €32.15 | −28% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 241.00 SAR | 112.37 SAR | −53% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.67 SGD | 1.44 SGD | −46% |
| Tenet Healthcare Corporation THC | $265.05 | $330.25 | +25% |
| DaVita Inc DVA | $183.99 | $186.49 | +1% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,818 | ₹2,955 | −66% |
| Fresenius Medical Care AG FMS | $23.50 | $46.42 | +98% |
| Aier Eye Hospital Group 300015 | ¥8.25 | ¥7.67 | −7% |
| Max Healthcare Institute Limited MAXHEALTH | ₹1,005 | ₹284.87 | −72% |
Compare EMEIS SA with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is EMEIS SA (EMEIS) overvalued or undervalued?
What is the fair value of EMEIS?
What is the quality score of EMEIS?
What is the price target for EMEIS SA (EMEIS)?
What is the EMEIS SA stock forecast for 2026?
What is the revenue of EMEIS SA (EMEIS)?
What is the net profit margin of EMEIS?
What growth is priced into EMEIS SA (EMEIS)?
What discount rate (WACC) does the fair value of EMEIS use?
What is the intrinsic value of EMEIS SA (EMEIS)?
Is EMEIS SA stock overvalued or undervalued in 2026?
Is fair value the same as the market price of EMEIS?
How much is EMEIS SA worth?
What do the bullish and bearish scenarios say about EMEIS?
What is the PEG ratio of EMEIS?
How solid is the balance sheet of EMEIS SA (EMEIS)?
How far is EMEIS from its 52-week high?
Which stocks are comparable to EMEIS SA?
Is EMEIS SA stock attractive at the current price?
How is the fair value of EMEIS calculated?
Is it still worth investing in stocks now?
Watch EMEIS SA in the live analysis
One click puts EMEIS SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.